In vivo RNAi delivery
Monday, 16 February, 2009
Invitrogen has launched its Invivofectamine delivery reagent, which enables siRNA experiments in vivo. As opposed to other offerings on the market, Invivofectamine delivery reagent can be injected in small volumes and without high pressure, minimising the potential of inconsistent results. It also provides extra stability to siRNA so the siRNA will arrive intact and ready to perform the selected knockdown. The reagent is non-viral and has minimal toxicity. Overall, these characteristics will enable researchers to more effectively optimize their siRNA experiments in vivo.
Invitrogen
www.invitrogen.com/invivornai
The last mile of life sciences innovation
How do we translate technological possibility into meaningful real-world impact?
Machine learning uncovers patterns in DNA methylation
A new machine-learning method identifies differentially methylated DNA regions without sample...
HRT linked to lower dementia risk in some women
Hormone replacement therapy may reduce the risk of dementia — particularly for certain...
